Objective

---

To deliver a data-driven framework for the comparative assessment of potential M&A targets, enabling strategic decisions which supports the client's growth strategy. The focus is on evaluating the clinical and regulatory potential of target assets, ensuring they align with the client's business objectives and contribute to portfolio growth.

Methodology

---

1. Customizable Framework:

• Develop a flexible framework for comparative assessment, tailored to include additional parameters as required using our AI platform.
• Key categories: Clinical Performance Benchmarking, Confidence Based on Clinical Trial Design, and Regulatory Success Considerations.

2. Category-Specific Analysis:

Clinical Performance Benchmarking:

• Compare efficacy and safety against the ideal Target Product Profile (TPP) and Standard of Care (SoC)
• Assess patient compliance factors.

Confidence Based on Clinical Trial Design:

• Evaluate the phase of development, sample size, trial design, and endpoints concerning regulatory acceptance.

Confidence Based on Clinical Trial Design:

• Analyse clinical success probability within the therapeutic area, development phase, and attrition rates.

3. Scoring and Weighting:

• The AI platform assigns and weights scores (1 to 5) across various parameters based on importance.
• Evaluate drugs using this scoring system and perform a comparative assessment.

4. Report Generation:

• Validate the analysis with cross-functional experts.
• Provide a detailed, evidence-based report to the client, supporting informed decisions and in-organic growth strategies.

Outcomes / Impact

---

• Informed Strategic Decision: The report delivers key insights for target selection, aligning with growth goals.
• Optimized Asset Integration: Ensures selected targets are poised for clinical and regulatory success, strengthening the client’s portfolio.
• Sustainable Growth: Supports the client’s M&A activities by providing a clear, strategic roadmap for growth.